It was learned yesterday that the pharmaceutical manufacturing industry in our city maintained steady growth in the first half of the year, and the industrial added value increased by 2.5 times over the same period last year. Among them, the pharmaceutical manufacturing industry and the special equipment manufacturing industry had a combined net output value of 19.086 billion yuan. Listed companies such as Deutsche Biotech have grown steadily.
As one of the city's key development of the 100 billion industrial chain, the city's biomedicine and health industry has formed an industrial cluster featuring medical devices and diagnostic reagents, and many companies have frequently emerged in China. For example, Dabo Medical, an orthopedic device company, is a rare orthopedic company with a full product line layout in China. Among them, the trauma business ranks first among domestic manufacturers, and the spine business ranks third among domestic manufacturers. In order to further accelerate the company's overall layout in the spine product line, combined with the trend of minimally invasive clinical spine surgery, Dabo Medical plans to acquire an enterprise of intervertebral foraminoscope equipment and supporting equipment consumables for RMB 93.71 million. % Equity. The latest data shows that Dabo Medical's operating income in the first half of the year was approximately 847 million yuan, an increase of 25.83% year-on-year; the net profit attributable to shareholders of listed companies was approximately 317 million yuan, an increase of 19.92% year-on-year.
At the same time, the city has strong original innovation capabilities in the fields of new vaccines, genetic engineering protein drugs, chemical drug preparation improvements, etc. In the first half of the year, biology and new drugs doubled, achieving an output value of 28.696 billion yuan, an increase of 2.3 times over the same period last year. The city’s first sci-tech innovation board company Tebao Bio-based chronic hepatitis B clinical cure research project is progressing smoothly. This is the world's first confirmatory clinical trial with clinical cure as the treatment goal, and all cases have been completed. Join the group. Its operating income in the first half of the year was approximately 469 million yuan, a year-on-year increase of 30.5%; the net profit attributable to shareholders of listed companies was approximately 72.1 million yuan, a year-on-year increase of 54.69%.
In addition, listed pharmaceutical companies such as Jindawei, Aide Biotech, and Luyan Pharmaceutical also achieved good results in the first half of the year. Statistics show that there are currently more than 1,000 biomedicine and health companies in our city, and 59 companies have output value or revenue exceeding 100 million yuan in the first half of the year.
Source: Chemical Network
